Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07637734 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

Study acronym: COVE-3
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment openedv2 Show 6 more changesShow less
    • Trial sites expanded: 2 → 20 locations
    • Primary completion moved earlier from Aug 2027 to May 2027
    • Study completion moved earlier from Oct 2027 to Jul 2027
    • Start date changed from estimate of Jun 2026 to Jun 15, 2026
    • Study description expanded, about 6 words
    • Eligibility criteria expanded, about 5 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.
Trial Details
NCT Number NCT07637734
Lead Sponsor Verrica Pharmaceuticals Inc.
Collaborators: Torii Pharmaceutical Co. Ltd., CMIC Co, Ltd. Japan, Canfield Scientific Inc., Medidata Solutions, Veeva Systems, Allucent (US) LLC, Myonex LLC
Conditions
(from sponsor)		 Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Related terms Warts
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov